Advanced search
Publication Cover
Journal of Inflammation Research Volume 14, 2021 - Issue
Submit an article Journal homepage
75
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy

Shihua Wang1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Yimeng Cui1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Minqi Xiong1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China;2 Clinical Research Institute of Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Mei Li1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Peiwei Wang1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China;2 Clinical Research Institute of Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Jingang Cui1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China;2 Clinical Research Institute of Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Xiaoye Du1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China;2 Clinical Research Institute of Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Yu Chen1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China;2 Clinical Research Institute of Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People’s Republic of China;3 Laboratory of Clinical and Molecular Pharmacology, Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaView further author information
&
Teng Zhang1 Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China;2 Clinical Research Institute of Integrative Medicine, Shanghai Academy of Traditional Chinese Medicine, Shanghai, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 1789-1806 | Published online: 05 May 2021

References

  • Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334–341.
  • Heinzel FR, Hohendanner F, Jin G, Sedej S, Edelmann F. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol. 2015;119:1233–1242.
  • Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476–2486.
  • Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580–1589.
  • Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011;13:1161–1171.
  • Hulsmans M, Sam F, Nahrendorf M. Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol. 2016;93:149–155.
  • Heymans S, Corsten MF, Verhesen W, et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013;128:1420–1432.
  • Kim JH. Cardiovascular diseases and panax ginseng: a review on molecular mechanisms and medical applications. J Ginseng Res. 2012;36:16–26.
  • Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol. 1999;58:1685–1693.
  • Zheng X, Wang S, Zou X, et al. Ginsenoside Rb1 improves cardiac function and remodeling in heart failure. Exp Anim. 2017;66:217–228.
  • Jiang QS, Huang XN, Dai ZK, et al. Inhibitory effect of ginsenoside Rb1 on cardiac hypertrophy induced by monocrotaline in rat. J Ethnopharmacol. 2007;111:567–572.
  • Jiang QS, Huang XN, Yang GZ, Jiang XY, Zhou QX. Inhibitory effect of ginsenoside Rb1 on calcineurin signal pathway in cardiomyocyte hypertrophy induced by prostaglandin F2alpha. Acta Pharmacol Sin. 2007;28:1149–1154.
  • Joh EH, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation–the key step of inflammation. Biochem Pharmacol. 2011;82:278–286.
  • Bian M, Du X, Wang P, et al. Combination of ginsenoside Rb1 and Rd protects the retina against bright light-induced degeneration. Sci Rep. 2017;7:6015.
  • Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy–from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754:253–262.
  • Dai DF, Johnson SC, Villarin JJ, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res. 2011;108:837–846.
  • Zhou B, Tian R. Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest. 2018;128:3716–3726.
  • Kumar AA, Kelly DP, Chirinos JA. Mitochondrial dysfunction in heart failure with preserved ejection fraction. Circulation. 2019;139:1435–1450.
  • Shirazi LF, Bissett J, Romeo F, Mehta JL. Role of inflammation in heart failure. Curr Atheroscler Rep. 2017;19:27.
  • Sager HB, Hulsmans M, Lavine KJ, et al. Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ Res. 2016;119:853–864.
  • Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res. 2014;114:266–282.
  • Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail. 2001;3:415–421.
  • Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension. 2010;56:225–231.
  • Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92:4862–4866.
  • Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21:965–973.
  • Zhao L, Cheng G, Jin R, et al. Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. Circ Res. 2016;118:1918–1929.
  • Corsten MF, Papageorgiou A, Verhesen W, et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res. 2012;111:415–425.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.